New markers in prostate biopsies;Nuevos marcadores en las biopsias de próstata

Actas Urologicas Espanolas

Volumn 31, Issue 9, 2007, Pages 1009-1024

  Molinie V ^a   Baumert, H ^a  

^a SAINT JOSEPH HOSPITAL   (France)

Author keywords

AMACR p504s; ASAP; Immunostaining p63; Minimal prostate cancer; Prostate cancer; Racemase

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; ISOMERASE; KERATIN; TUMOR MARKER; UNCLASSIFIED DRUG;

BIOPSY; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; HUMAN; MALE; PATHOLOGY; PROSTATE TUMOR; REVIEW;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; HUMANS; KERATINS; MALE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; TUMOR MARKERS, BIOLOGICAL;

EID: 41649097634     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(07)73764-6     Document Type: Review

References (53)

1. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol. 2004;17(3):307-315.
2. Evans AJ. Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol. 2003;56(12): 892-897.
3. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol. 2005;22(1):88-104.
4. Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med. 2000;124 (1):98-107.
5. Srigley JR: Benign mimickers of prostatic adenocarcinoma. Mod Pathol. 2004; 17(3):328-348.
6. Molinie V. Minute focus, suspected focus and high-grade prostatic intraepithelial neoplasia. What is the significance? What are the consequences?. Prog Urol. 2004;14(1 Suppl): 2-6.
7. Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. Am J Clin Pathol. 2000l;114 (6):896-909.
8. Davis LD, Zhang W, Merseburger A, Young D, Xu L, Rhim JS et al. p63 expression profile in normal and malignant prostate epithelial cells. Anticancer Res. 2002; 22(6c): 3819-3825.
9. Helpap B, Kollermann J, Oehler U. Limiting the diagnosis of atypical small glandular proliferations in needle biopsies of the prostate by the use of Immunohistochemistry. J Pathol. 2001;193(3):350-353.
10. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001;58(4):619-624.
11. Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol. 2004; 122(4):517-523.
12. Carella R, Deleonardi G, D'Errico A, Salerno A, Egarter-Vigl E, Seebacher C et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol. 2001;25(1):43-50.
13. Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins. III. Analysis of tumors. Am J Clin Pathol. 1985; 84(4):413-424.
14. Jiang Z, Iczkowski KA, Woda BA, Tretiakova M, Yang XJ. P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens. Am J Clin Pathol. 2004; 121(1):99-107.
15. Jiang Z, Li C, Fischer A, Dresser K, Woda BA. Using an AMACR (P504S)/ 34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005; 123(2):231-236.
16. Hedrick L, Epstein JI. Use of keratin 9 3 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol. 1989;13(5):389-396.
17. Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol. 1999;23(2):147-152.
18. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology. 2002;41(1):35-41.
19. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol. 2002;15(1):6-10.
20. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40(5):403-39.
21. Molinie V, Fromont G, Sibony M, Vieillefond A, Vassiliu V, Cochand-Priollet B et al. Diagnostic utility of a p63/ alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol. 2004;17(10):1180-1190.
22. Molinie V, Herve JM, Lebret T, Lugagne-Delpon PM, Saporta F, Yonneau L et al. Value of the antibody cocktail anti p63 + anti p504s for the diagnosis of prostatic cancer. Ann Pathol. 2004;24(1):6-16.
23. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 2005;47(1):1-16.
24. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol. 2000;1(3):199-207.
25. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157 (6):1769-1775.
26. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002;15(12):1302-1308.
27. Molinie V, Herve JM, Lugagne PM, Baglin AC. P63 and p504s cocktail is useful in ambiguous lesions of the prostate. Histopathology. 2004;44(4):403-404.
28. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26(9):1161-1168.
29. Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am J Surg Pathol. 2003:27(3):365-371.
30. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG et al. Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. Jama. 2002;287(13):1662-1670.
31. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25(11):1397-1404.
32. Jiang Z, Wu CL, Woda BA, Xu Y, Savas L, Khan A et al. P504S/ alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26(9):1169-1174.
33. Leav I. McNeal JE, Ho SM, Jiang Z. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasla and in cancers of the transition zone. Hum Pathol. 2003;34(3):228-233.
34. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL. Bennett CJ et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62(8):2220-2226.
35. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol. 2003;27(8):1128-1133.
36. Sanderson SO, Sebo TJ, Murphy LM, Neumann R, Slezak J, Cheville JC. An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays. Am J Clin Pathol, 2004;121(2):220-225.
37. Yang XJ, Wu CL, Woda BA, Dresser K, Tretiakova M, Fanger GR et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol. 2002;26(7):921-925.
38. Zhou M, Aydin H, Kanane H, Epstein JI. How often does ai ba-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?. Am J Surg Pathol 2004;28(2):239-243.
39. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer. Am J Surg Pathol. 2003;27(6):772-778.
40. Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000;60(6):1677-1682.
41. Beach R, Gown AM, De Peralta-Venturina MN, Folpe AL. Yaziji H, Salles PG et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26(12): 1588-1596.
42. Schostak M KH, Köllermann J, Schrader M, Miller K. Quantitative real-time RT-PCR for AMACR distinguishes prostate cancer with High specificity from benign lesions. J Urol. 2005; 173:531S (Abstract).
43. Kunju LP, Rubin MA, Chinnaiyan AM, Shah RB. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clin Pathol. 2003;120(5):737-745.
44. Yang XJ, Laven B, Tretiakova M, Blute RD Jr, Woda BA, Steinberg GD et al. Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma. Urology. 2003;62(2):282-286.
45. Farinola MA, Epstein JI. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol. 2004;35(10):1272-1278.
46. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol. 2005;295):579-587.
47. Herawi M, Parwani AV, Irie J, Epstein JI. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol. 2005;29(7):874-880.
48. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26(7):926-931.
49. Wu CL, Yang XJ, Tretiakova M, Patton KT, Halpern EF, Woda BA et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepíthelial neoplasia. Hum Pathol. 2004;35(8):1008-1013.
50. Molinie V, Herve JM, Lugagne PM, Yonneau L, Ellard S, Lebret T et al. Value of new prostate cancer markers: alpha methylacyl CoA racemase (P504S) and p63. Prog Urol. 2005;15(4):611-615.
51. Jiang Z, Woda BA, Wu CL, Yang XJ. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol. 2004;122(2):275-289.
52. Goldstein NS. Immunophenotypic characterization of 225 prostate acadenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002; 117:471-417.
53. Varma M, Morgan M, Jasani B, Tamboli P, Amin MB. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology. Am J Clin Pathol. 2002;118(2):202-207.